Hurwitz MD - Search Results

1

A paradigm shift from anatomic to functional and molecular imaging in the detection of recurrent prostate cancer.

Zaorsky NG, Yamoah K, Thakur ML, Trabulsi EJ, Showalter TN, Hurwitz MD, Dicker AP, Den RB. Zaorsky NG, et al. Among authors: hurwitz md. Future Oncol. 2014 Feb;10(3):457-74. doi: 10.2217/fon.13.196. Future Oncol. 2014. PMID: 24559451 Free PMC article. Review.

2

Comparing PSA outcome after radical prostatectomy or magnetic resonance imaging-guided partial prostatic irradiation in select patients with clinically localized adenocarcinoma of the prostate.

D'amico AV, Tempany CM, Schultz D, Cormack RA, Hurwitz M, Beard C, Albert M, Kooy H, Jolesz F, Richie JP. D'amico AV, et al. Urology. 2003 Dec;62(6):1063-7. doi: 10.1016/s0090-4295(03)00772-6. Urology. 2003. PMID: 14665356

3

Pretreatment predictors of posttreatment PSA doubling times for patients undergoing three-dimensional conformal radiotherapy for clinically localized prostate cancer.

Beard C, Chen MH, Cote K, Loffredo M, Renshaw A, Hurwitz M, D'Amico AV. Beard C, et al. Urology. 2005 Nov;66(5):1020-3. doi: 10.1016/j.urology.2005.05.039. Urology. 2005. PMID: 16286116

4

Updated results of magnetic resonance imaging guided partial prostate brachytherapy for favorable risk prostate cancer: implications for focal therapy.

Nguyen PL, Chen MH, Zhang Y, Tempany CM, Cormack RA, Beard CJ, Hurwitz MD, Suh WW, D'Amico AV. Nguyen PL, et al. Among authors: hurwitz md. J Urol. 2012 Oct;188(4):1151-6. doi: 10.1016/j.juro.2012.06.010. Epub 2012 Aug 15. J Urol. 2012. PMID: 22901567 Free PMC article.

5

Evolution of advanced technologies in prostate cancer radiotherapy.

Zaorsky NG, Harrison AS, Trabulsi EJ, Gomella LG, Showalter TN, Hurwitz MD, Dicker AP, Den RB. Zaorsky NG, et al. Among authors: hurwitz md. Nat Rev Urol. 2013 Oct;10(10):565-79. doi: 10.1038/nrurol.2013.185. Epub 2013 Sep 10. Nat Rev Urol. 2013. PMID: 24018567 Review.

6

Do theoretical potential and advanced technology justify the use of high-dose rate brachytherapy as monotherapy for prostate cancer?

Zaorsky NG, Doyle LA, Hurwitz MD, Dicker AP, Den RB. Zaorsky NG, et al. Among authors: hurwitz md. Expert Rev Anticancer Ther. 2014 Jan;14(1):39-50. doi: 10.1586/14737140.2013.836303. Expert Rev Anticancer Ther. 2014. PMID: 24124755 Review.

7

Combining theoretical potential and advanced technology in high-dose rate brachytherapy boost therapy for prostate cancer.

Zaorsky NG, Den RB, Doyle LA, Dicker AP, Hurwitz MD. Zaorsky NG, et al. Among authors: hurwitz md. Expert Rev Med Devices. 2013 Nov;10(6):751-63. doi: 10.1586/17434440.2013.841347. Expert Rev Med Devices. 2013. PMID: 24195459 Review.

8

High dose rate brachytherapy boost for prostate cancer: a systematic review.

Zaorsky NG, Doyle LA, Yamoah K, Andrel JA, Trabulsi EJ, Hurwitz MD, Dicker AP, Den RB. Zaorsky NG, et al. Among authors: hurwitz md. Cancer Treat Rev. 2014 Apr;40(3):414-25. doi: 10.1016/j.ctrv.2013.10.006. Epub 2013 Oct 26. Cancer Treat Rev. 2014. PMID: 24231548 Review.

9

The quality frontier.

Hurwitz MD, Dicker AP. Hurwitz MD, et al. Future Oncol. 2014 Mar;10(4):563-7. doi: 10.2217/fon.13.226. Future Oncol. 2014. PMID: 24754588 Review.

10

Large prostate gland size is not a contraindication to low-dose-rate brachytherapy for prostate adenocarcinoma.

Yamoah K, Eldredge-Hindy HB, Zaorsky NG, Palmer JD, Doyle LA, Sendecki JA, Hesney AA, Harper L, Repka M, Showalter TN, Hurwitz MD, Dicker AP, Den RB. Yamoah K, et al. Among authors: hurwitz md. Brachytherapy. 2014 Sep-Oct;13(5):456-64. doi: 10.1016/j.brachy.2014.04.003. Epub 2014 Jun 18. Brachytherapy. 2014. PMID: 24953945

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

85 results

Search Page